标题: |
先天性肾上腺皮质增生症21羟化酶缺陷症生长发育管理专家共识 |
title: |
Expert consensus on growth and development management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
版本: |
原创版 |
version: |
Original |
分类: |
专家共识 |
classification: |
Experts consensus |
领域: |
管理 |
field: |
Administration |
国家和地区: |
中国 |
Country and
region:
|
China |
指南使用者: |
内分泌科及儿科专科医生 |
Guide users:
|
Endocrinologists and Paediatricians |
证据分级方法: |
依据牛津循证医学中心(OCEBM)证据分级方法,将纳入的研究证据分为6个证据等级(1a、1b、2a、2b、3、4),并根据证据等级将推荐强度分为A(强)、B(中)、C(弱)3级,以代表共识制订专家组的建议。 |
Evidence grading
method:
|
According to the evidence ranking schemes from Oxford Centre for Evidence-Based Medicine (OCEBM) , the evidence from the included studies will be divided into 6 levels of evidence (1a, 1b, 2a, 2b, 3, 4), and the strength of the recommendation will be divided into 3 levels according to the level of evidence: A (strong), B (moderate), and C (weak). |
制定单位: |
中国医学科学院北京协和医院 |
Formulating unit: |
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences |
注册时间: |
2024-03-25 |
Registration time: |
注册编号: |
PREPARE-2024CN460 |
Registration number: |
指南制订的目的: |
规范21羟化酶缺陷症患者的生长发育治疗和监测,帮助专科医生在21羟化酶缺陷症的儿童生长发育管理中做到准确评估、规范诊治、避免误区。 |
Purpose of the guideline:
|
To standardize the treatment and monitoring of growth and development in patients with 21-hydroxylase deficiency, and help specialists to accurately assess, standardize diagnosis and treatment, and avoid misunderstandings in the growth and development management of children with 21-hydroxylase deficiency. |